Scholarlink

Purpose <p>The eyeWatch™ implant is a novel glaucoma drainage device allowing for a titratable aqueous humour outflow via an external magnetic control unit, facilitating a more controlled reduction in intraocular pressure. We report on 12&#xa0;month outcomes evaluating the safety and efficacy of eyeWatch™ implant combined with an eyePlate (eyeWatch™ system) in refractory glaucoma.</p> Methods <p>Prospective study including patients aged 18&#xa0;years or older with refractory primary open angle, pigmentary or pseudoexfoliative glaucomas with elevated intraocular pressures &gt; 20&#xa0;mmHg and previous failed filtration surgery were included. Patients underwent implantation of the eyeWatch™ system. Outcomes were analysed post operatively on 1&#xa0;day, 1&#xa0;week, 2&#xa0;week, 1&#xa0;month, 2&#xa0;months, 3&#xa0;months, 6&#xa0;months and 12&#xa0;months after surgery. Main outcome measures were intraocular pressure reduction by ≥ 20% or intraocular pressure &lt; 21&#xa0;mmHg and no intraocular pressure &lt; 6&#xa0;mmHg on two consecutive visits after 12&#xa0;months. Secondary outcomes were mean visual acuity, intraocular pressure and anti-glaucoma medications usage.</p> Results <p>Twenty-seven patients were enrolled with a mean age of 68.9 ± 9.5&#xa0;years. At 12&#xa0;months, mean reduction of IOP was from 24.4 ± 5.2&#xa0;mmHg at baseline to 13.2 ± 4.8&#xa0;mmHg (<i>p</i> &lt; 0.01). The number of anti-glaucoma medications significantly decreased from 3.1 ± 0.7 (baseline) to 1.1 ± 1.1 (<i>p</i> &lt; 0.01). Visual acuity remained stable for almost all patients from 0.37 ± 0.32 to 0.39 ± 0.26 (logMAR). Complete success rate (intraocular pressure within defined range without glaucoma medications) was 47% and overall success rate was 93%.</p> Conclusions <p>The eyeWatch™ system allows for peri and postoperative non-invasive adjustments to resistance of aqueous humour outflow. At 12&#xa0;months the majority of patients experienced adequate intraocular pressure control, with over 47% not requiring anti-glaucoma medications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short term clinical outcomes of the combined eyeWatch™ implant and eyePlate in refractory glaucoma—a United Kingdom dual centre study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月24日

查看全文
  • Andrew J. Swampillai,
  • Leon Au,
  • Kin Sheng Lim

摘要

Purpose

The eyeWatch™ implant is a novel glaucoma drainage device allowing for a titratable aqueous humour outflow via an external magnetic control unit, facilitating a more controlled reduction in intraocular pressure. We report on 12 month outcomes evaluating the safety and efficacy of eyeWatch™ implant combined with an eyePlate (eyeWatch™ system) in refractory glaucoma.

Methods

Prospective study including patients aged 18 years or older with refractory primary open angle, pigmentary or pseudoexfoliative glaucomas with elevated intraocular pressures > 20 mmHg and previous failed filtration surgery were included. Patients underwent implantation of the eyeWatch™ system. Outcomes were analysed post operatively on 1 day, 1 week, 2 week, 1 month, 2 months, 3 months, 6 months and 12 months after surgery. Main outcome measures were intraocular pressure reduction by ≥ 20% or intraocular pressure < 21 mmHg and no intraocular pressure < 6 mmHg on two consecutive visits after 12 months. Secondary outcomes were mean visual acuity, intraocular pressure and anti-glaucoma medications usage.

Results

Twenty-seven patients were enrolled with a mean age of 68.9 ± 9.5 years. At 12 months, mean reduction of IOP was from 24.4 ± 5.2 mmHg at baseline to 13.2 ± 4.8 mmHg (p < 0.01). The number of anti-glaucoma medications significantly decreased from 3.1 ± 0.7 (baseline) to 1.1 ± 1.1 (p < 0.01). Visual acuity remained stable for almost all patients from 0.37 ± 0.32 to 0.39 ± 0.26 (logMAR). Complete success rate (intraocular pressure within defined range without glaucoma medications) was 47% and overall success rate was 93%.

Conclusions

The eyeWatch™ system allows for peri and postoperative non-invasive adjustments to resistance of aqueous humour outflow. At 12 months the majority of patients experienced adequate intraocular pressure control, with over 47% not requiring anti-glaucoma medications.